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ABSTRACT 
Objective: Synthesis and analgesic, anti-inflammatory and antimicrobial evaluation of some novel Schiff and Mannich bases of isatin derivatives. 
Methods: A series of novel 3-(4-(2-(substituted benzylideneamino)thiazol-4-yl)phenylimino)-1-((dimethylamino)methyl)-5-fluoroindolin-2-one 
Schiff and Mannich base derivatives were synthesized by using various aromatic aldehydes with isatin derivatives. The chemical structures of all 
synthesized compounds were confirmed by IR, 1
Results: The results of analgesic, anti-inflammatory and antimicrobial activity showed that some of the synthesized compounds were exhibited 
promising results.  
H-NMR, Mass spectra and elemental analysis. All the synthesized compounds were screened for its 
analgesic, anti-inflammatory and antimicrobial activity.  
Conclusion: This investigation identified the potent analgesic, anti-inflammatory and anti-microbial agents and these molecules will be subjected to 
further studies in our laboratory. 
Keywords: Schiff bases, Mannich bases, Isatin, Anti-microbial activity.  
 
INTRODUCTION 
The treatment of infectious diseases remains an important issue 
because of a combination of factors including emerging newer 
infectious diseases and growing number of multi-drug resistant 
microbial pathogens. The therapeutic crisis is an important part of 
hospitalized patients, immune suppressed patients with AIDS and 
those undergoing anticancer therapy or organ transplants. Despite a 
large number of antibiotics and chemotherapeutics available for 
medical use, the emerging resistance to old and new antibiotics has 
created a substantial need for new classes of antimicrobial agents. A 
potential solution to the antibiotic resistance is to design and 
explore innovative heterocyclic agents with novel mode of actions. 
The potentiality of non-steroidal anti-inflammatory drugs (NSAID) 
to alleviate pain, inflammation and fever coupled with a number of 
pathological conditions made them the most useful therapeutic 
agents in the world. However, the routine use of these agents was 
reported to be limited because of their associated side effects mainly 
on gastrointestinal (GI) tracts. Pain is an unpleasant sensory and 
emotional experience associated with actual or potential organ and 
tissue damage. Body inflammation is a unique pain inducer which 
the human kind faces more often as an outcome of tissue damage 
developed by a series of microbial infections such as anorexia, pain 
and fever which in turn shoots up the body temperature. In order to 
combat these diseases caused by pathogens, it is usual that 
chemotherapeutics, analgesic and antipyretic agents are prescribed 
separately in clinical practices. However, multidrug treatments for 
microbial diseases create a significant problem among the patients 
with impaired organ functions. This laid the foundation for the 
search and design of new chemical agents which are devoid of all the 
limitations and side effects of the drugs available in the market. 
Hence, there is an urgent need for mono therapy with a biologically 
potent candidate endowed with anti-microbial, analgesic and anti-
inflammatory activities together by keeping in view the pharmaco-
economic and frequent patient compliance. Among the important 
heterocyclic pharmacophores responsible for biological activity, the 
isatin scaffold is viable lead structure for the synthesis of efficient 
chemotherapeutic agent [1]. Schiff and mannich bases derived from 
isatin exhibit many neuro physiological and neuro pharmacological 
effects like antimicrobial, antiviral, anticonvulsant, anticancer, anti-
mycobacterial, antimalarial, cysticidal, herbicidal and anti-
inflammatory activities [2-7]. In addition, they also have anti-HIV, 
anti-protozoal and anti-helminthic activities [8-11]. Recently they 
have found application as enzyme inhibitors in the inhibition of 
cysteine and serine proteases [12]. Azoles constitute immensely 
important members of the aromatic heterocycle family due to their 
presence in a myriad of bioactive natural products as privileged 
pharmacophores. Thiazoles are a familiar group of heterocyclic 
compounds possessing a wide variety of biological activities, and 
their usefulness as medicines are well established. Thiazole nucleus 
is also an integral part of all the available penicillins, which have 
revolutionized the therapy of bacterial diseases [13]. Further, 
thiazoles have emerged as new class of potent antimicrobial agents, 
which are reported to inhibit bacteria by blocking the biosynthesis 
of certain bacterial lipids and/or by additional mechanisms [14, 15]. 
Encouraged by aforementioned observations, we aimed to 
synthesize novel, potent, selective, and less toxic antimicrobial, 
analgesic and anti-inflammatory agents. We report herein the 
synthesis of some novel Schiff and Mannich bases of structural 
hybrids by combining isatin and thiazole pharmacophores in single 
molecular framework in order to investigate there in vitro 
antimicrobial, analgesic and anti-inflammatory activity. 
MATERIALS AND METHODS 
All solvents used were of laboratory grade and were obtained from 
SD fine chemicals (Mumbai, India), and Merck (Mumbai, India). 
Ciprofloxacin and Ketoconazole are received as gift samples from Dr. 
Reddys laboratories, Hyderabad, India. Diclofenac and aspirin are 
received as gift samples from Kemwell Biopharma, Bangalore, India. 
Melting points were determined in open glass capillary tubes and 
are uncorrected. Compounds were routinely checked for their purity 
on Silica gel G (Merck) Thin layer chromatography (TLC) plates. 
Iodine chamber and UV lamp were used for visualization of TLC 
spots. The IR spectra were recorded in KBr pellets on (BIO-RAD FTS) 
FT-IR spectrophotometer. 1H-NMR spectra were recorded on Bruker 
DPX-400 NMR spectrometer in DMSO-d6 using tetramethylsilane 
(TMS) as an internal standard. The chemical shifts are reported in 
ppm scale. Elemental data for C, H, and N were within ±0.4% of the 
theoretical values. 
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General Procedure for the synthesis of title compounds (5a-5l) 
Preparation of 3-(4-acetylphenylimino)-5-fluoroindolin-2-one (2) 
Equimolar quantities (0.1 mol) of 5-fluoro isatin and para amino 
acetophenone were dissolved in warm ethanol containing few ml of 
glacial acetic acid. The reaction mixture was refluxed for 3 h and set 
aside. The resultant product was collected and washed with dilute 
ethanol.  
Yield: 71%; Mp: 196-198; FT-IR (KBr): cm-1 3368 (NH); 2939 (Ar C–
H); 1732 (C=O); 1692 (C=O, isatin); 1636 (C=N); 1H NMR (400 MHz, 
δ ppm): 2.22 (s, 3H, -CH3); 6.64–7.66 (m, 7H, Ar-CH); 8.30 (s, 1H, -
NH); MS (EI) m/z: 282 [M+]; Anal. Calcd for C16H11FN2O2
Preparation of 3-(4-acetylphenylimino)-1-((dimethylamino) 
methyl)-5-fluoroindolin-2-one (3) 
: C, 68.08; 
H, 3.93; N, 9.92; Found: C, 68.12; H, 3.91 N, 9.86. 
To the solution of 3-(4-acetylphenylimino)-5-fluoroindolin-2-one 
(2) (0.05 mol) in 95% absolute ethanol (100 mL), aqueous 
formaldehyde 37% (1.0 mL) was added. Then dimethylamine (0.05 
mol) added slowly to the above solution under stirring. After the 
addition was over, the entire reaction mixture was stirred at room 
temperature for 3 h, and then kept aside for 48 h in refrigerator to 
form crystals. Finally the products in the form of crystals were 
separated by filtration, and vacuum dried. Desired compounds were 
finally recrystallized with ethanol to obtain pure product.  
Yield: 68%; Mp: 212-214; FT-IR (KBr): cm-1 2957 (Ar C–H); 1710 
(C=O); 1682 (C=O, isatin); 1662 (C=N); 1H NMR (400 MHz, δ ppm): 
2.32 (s, 3H, -CH3); 2.62 (s, 6H, N-(CH3)2); 4.54 (s, 2H, -CH2); 6.42–
7.56 (m, 7H, Ar-CH); MS (EI) m/z: 339 [M+]; Anal. Calcd for 
C19H18FN3O2
Preparation of 3-(4-(2-aminothiazol-4-yl) phenylimino)-1-
((dimethylamino) methyl)-5-fluoroindolin-2-one (4) 
: C, 67.24; H, 5.35; N, 12.38; Found: C, 67.36; H, 5.36; N, 
12.40.  
The thiazole ring was formed by the reaction of 3-(4-acetyl 
phenylimino)-1-((dimethylamino)methyl)-5-fluoroindolin-2-one 
(0.2 mol) (3) with thiourea (0.4 mol) and bromine (0.4 mol). The 
entire reaction mixture was boiled overnight in a water bath, and 
water was added to it and again heated until most of the solid has 
gone into solution. The solution was filtered when it was hot and the 
filtrate was cooled. Finally the filtrate was made alkaline with 
concentrated ammonium hydroxide to separate 3-(4-(2-
aminothiazol-4-yl)phenylimino)-1-((dimethylamino)methyl)-5-
fluoroindolin-2-one (4). The formed product was recrystallized with 
ethanol. 
Yield: 68%; Mp: 192-194; FT-IR (KBr): cm-1 2920 (Ar C–H); 1736 
(C=O); 1686 (C=O, isatin); 1669 (C=N); 1H NMR (400 MHz, δ ppm): 
2.58 (s, 6H, N-(CH3)2); 4.33 (s, 2H, -CH2); 4.74 (s, 2H, -NH2); 6.68–
7.64 (m, 8H, Ar-CH); MS (EI) m/z: 395 [M+]; Anal. Calcd for 
C20H18FN5
Synthesis of 3-(4-(2-(substituted benzylideneamino)thiazol-4-
yl)phenylimino)-1-((dimethylamino)methyl)-5-fluoroindolin-
2-one (5a-51) 
OS: C, 60.74; H, 4.59; N, 17.71; Found: C, 60.60; H, 4.60; N, 
17.72. 
Title compounds (5a-5l) were synthesized by adding 3-(4-(2-
aminothiazol-4-yl)phenylimino)-1-((dimethylamino)methyl)-5-
fluoroindolin-2-one (4) (0.01 mol) in fraction with the well stirred 
mixture of different aromatic aldehydes (0.01 mol) in ethanol (50 
mL) and glacial acetic acid (few mL). Then this mixture was refluxed 
for 6 h and kept aside. The product that separated out was filtered, 
dried and recrystallized from ethanol. The method used for the 
preparation and isolation of the compounds gave materials of good 
purity, as evidenced by their spectral analyses.  
3-(4-(2-(Benzylideneamino)thiazol-4-yl)phenylimino)-1-
((dimethylamino)methyl)-5-fluoroindolin-2-one (5a) 
FT-IR (KBr): cm-1 3025 (Ar C–H); 1741 (C=O); 1675 (C=N); 1H NMR 
(400 MHz, δ ppm): 2.45 (s, 6H, N-(CH3)2); 4.36 (s, 2H, -CH2); 6.78–
7.68 (m, 13H, Ar-CH); 8.36 (s, 1H, -CH=N); MS (EI) m/z: 483 [M+]; 
Anal. Calcd for C27H22FN5
3-(4-(2-(4-Methylbenzylideneamino)thiazol-4-yl)phenylimino) 
-1-((dimethylamino)methyl)-5-fluoroindolin-2-one (5b) 
OS: C, 67.06; H, 4.59; N, 14.48; Found: C, 
67.15; H, 4.60; N, 14.50. 
FT-IR (KBr): cm-1 3024 (Ar C–H); 1741 (C=O); 1591 (C=N); 1H NMR 
(400 MHz, δ ppm): 2.22 (s, 3H, -CH3); 2.58 (s, 6H, N-(CH3)2); 4.23 (s, 
2H, -CH2); 6.65–7.80 (m, 12H, Ar-CH); 8.24 (s, 1H, -CH=N); MS (EI) 




OS: C, 67.59; H, 4.86; N, 
14.07; Found: C, 67.42; H, 4.85; N, 14.05. 
FT-IR (KBr): cm-1 3390 (Ar-OH); 2917 (Ar C–H); 1736 (C=O); 1574 
(C=N); 1H NMR (400 MHz, δ ppm): 2.64 (s, 6H, N-(CH3)2); 3.82 (s, 
3H, Ar-OCH3); 4.26 (s, 2H, -CH2); 5.10 (s, 1H, Ar-OH); 6.77–7.66 (m, 





S: C, 63.50; H, 4.57; N, 13.22; Found: C, 63.38; H, 
4.55; N, 13.24. 
FT-IR (KBr): cm-1 3024 (Ar C–H); 1741 (C=O); 1593 (C=N); 1H NMR 
(400 MHz, δ ppm): 2.54 (s, 6H, N-(CH3)2); 3.12 (s, 6H, N-(CH3)2); 
4.26 (s, 2H, -CH2); 6.74–7.65 (m, 12H, Ar-CH); 8.22 (s, 1H, -CH=N); 




OS: C, 66.14; H, 
5.17; N, 15.96; Found: C, 66.20; H, 5.18; N, 15.98. 
FT-IR (KBr): cm-1 2970 (Ar C–H); 1740 (C=O); 1593 (C=N); 1H NMR 
(400 MHz, δ ppm): 2.60 (s, 6H, N-(CH3)2); 3.26 (s, 3H, -OCH3); 4.18 
(s, 2H, -CH2); 6.58–7.64 (m, 12H, Ar-CH); 8.26 (s, 1H, -CH=N); MS 




S: C, 65.48; H, 4.71; 
N, 13.64; Found: C, 65.58; H, 4.72; N, 13.64. 
FT-IR (KBr): cm-1 2970 (Ar C–H); 1741 (C=O); 1593 (C=N); 1H NMR 
(400 MHz, δ ppm): 2.44 (s, 6H, N-(CH3)2); 3.54 (s, 9H, (OCH3)3); 
4.24 (s, 2H, -CH2); 6.84–7.82 (m, 10H, Ar-CH); 8.18 (s, 1H, -CH=N); 
MS (EI) m/z: 573 [M+]; Anal. Calcd for C30H28FN5O4
3-(4-(2-(4-Chlorobenzylideneamino)thiazol-4-yl)phenylimino)-
1-((dimethylamino)methyl)-5-fluoroindolin-2-one (5g) 
S: C, 62.81; H, 
4.92; N, 12.21; Found: C, 62.70; H, 4.91; N, 12.20. 
FT-IR (KBr): cm-1 2938 (Ar C–H); 1753 (C=O); 1612 (C=N); 746 (C-
Cl); 1H NMR (400 MHz, δ ppm): 2.48 (s, 6H, N-(CH3)2); 4.32 (s, 2H, -
CH2); 6.48–7.54 (m, 12H, Ar-CH); 8.34 (s, 1H, -CH=N); MS (EI) m/z: 
520 (M+2); Anal. Calcd for C27H21ClFN5O3
3-(4-(2-(2-Chlorobenzylideneamino)thiazol-4-yl)phenylimino)-
1-((dimethylamino)methyl)-5-fluoroindolin-2-one (5h) 
S: C, 62.60; H, 4.09; N, 
13.52; Found: C, 62.72; H, 4.10; N, 13.50. 
FT-IR (KBr): cm-1 2980 (Ar C–H); 1753 (C=O); 1633 (C=N); 747 (C-
Cl); 1H NMR (400 MHz, δ ppm): 2.54 (s, 6H, N-(CH3)2); 4.16 (s, 2H, -
CH2); 6.55–7.64 (m, 12H, Ar-CH); 8.18 (s, 1H, -CH=N); MS (EI) m/z: 
518 [M+]; Anal. Calcd for C27H21ClFN5O3
3-(4-(2-(4-Nitrobenzylideneamino)thiazol-4-yl)phenylimino)-
1-((dimethylamino)methyl)-5-fluoroindolin-2-one (5i) 
S: C, 62.60; H, 4.09; N, 
13.52; Found: C, 62.50; H, 4.08; N, 13.51. 
FT-IR (KBr): cm-1 2970 (Ar C–H); 1741 (C=O); 1589 (C=N); 1555, 
1369 (NO2); 1H NMR (400 MHz, δ ppm): 2.54 (s, 6H, N-(CH3)2); 4.36 
(s, 2H, -CH2); 6.62–7.74 (m, 12H, Ar-CH); 8.26 (s, 1H, -CH=N); MS 
(EI) m/z: 528 [M+]; Anal. Calcd for C27H21FN6O3S: C, 61.35; H, 4.00; 
N, 15.90; Found: C, 61.48; H, 3.99; N, 15.92. 
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FT-IR (KBr): cm-1 2940 (Ar C–H); 1752 (C=O); 1612 (C=N); 1547, 
1350 (NO2); 1H NMR (400 MHz, δ ppm): 2.62 (s, 6H, N-(CH3)2); 4.36 
(s, 2H, -CH2); 6.84–7.92 (m, 12H, Ar-CH); 8.2 (s, 1H, -CH=N); MS (EI) 




S: C, 61.35; H, 4.00; N, 
15.90; Found: C, 61.40; H, 4.01; N, 15.89. 
FT-IR (KBr): cm-1 3415 (OH); 2914 (Ar C–H); 1731 (C=O); 1642 
(C=N); 1H NMR (400 MHz, δ ppm): 2.48 (s, 6H, N-(CH3)2); 4.14 (s, 
2H, -CH2); 5.25 (s, 1H, -OH); 6.66–7.74 (m, 12H, Ar-CH); 8.18 (s, 1H, -





64.91; H, 4.44; N, 14.02; Found: C, 65.04; H, 4.43; N, 14.01. 
FT-IR (KBr): cm-1 3424 (OH); 2914 (Ar C–H); 1723 (C=O); 1643 
(C=N); 1H NMR (400 MHz, δ ppm): 2.54 (s, 6H, N-(CH3)2); 4.26 (s, 
2H, -CH2); 5.24 (s, 1H, -OH); 6.54–7.68 (m, 12H, Ar-CH); 8.26 (s, 1H, -
CH=N); MS (EI) m/z: 499 [M+]; Anal. Calcd for C27H22FN5O2
Biological activities 
S: C, 
64.91; H, 4.44; N, 14.02; Found: C, 64.84; H, 4.42; N, 14.04. 
Pharmacology 
The synthesized compounds were evaluated for analgesic, anti-
inflammatory, and ulcerogenic activities. One-way analysis of 
variance (ANOVA) was performed to certain the significance of all 
the exhibited activities. The test compounds and the standard drugs 
were administered in the form of a suspension (1% carboxy methyl 
cellulose as a vehicle) by oral route of administration for analgesic 
and anti-inflammatory but for ulcerogenicity studies by 
intraperitoneally as suspension in 10% v/v Tween-80. Each group 
consisted of six animals. The animals were maintained in colony 
cages at 25 ± 2°C, relative humidity of 45–55%, under a 12 h light 
and dark cycle; were fed standard animal feed [16]. All the animals 
were acclimatized for a week before use. 
Analgesic activity 
The analgesic activity was performed by tail-flick technique using 
Wistar albino mice (25–35 g) of either sex selected by random 
sampling technique [17,18]. Diclofenac sodium at a dose level of 10 
and 20 mg/kg was administered orally as reference drug for 
comparison. The test compounds at two dose levels i. e., 10 and 20 
mg/kg were administered orally. The reaction times were recorded 
immediately before and 30 min, 1, 2, and 3 h after the treatment and 
cut-off time was 10 s. The percent analgesic activity (PAA) was 
calculated by the following formula. PAA = [T2-T1/10-T1] X 100; 
where T1 is the reaction time (s) before treatment, and T2 is the 
reaction time (s) after treatment.  
Anti-inflammatory activity  
Anti-inflammatory activity was evaluated by carrageenan induced 
paw edema test in rats [19]. Diclofenac sodium 10 and 20 mg/kg 
was administered as standard drug for comparison. The test 
compounds were administered at two dose levels of 10 and 20 
mg/kg. The paw volumes were measured using the mercury 
displacement technique with the help of plethysmograph 
immediately before and 30 min, 1, 2, and 3 h after carrageenan 
injection.  
The percent inhibition of paw edema was calculated according to the 
following formula, percent inhibition I = 100[1 - (a - x)/(b - y)], 
where x is the mean paw volume of rats before the administration of 
carrageenan and test compounds or reference compound (test 
group), a is the mean paw volume of rats after the administration of 
carrageenan in the test group (drug treated), b is the mean paw 
volume of rats after the administration of carrageenan in the control 
group, y is the mean paw volume of rats before the administration of 
carrageenan in the control group. All the percent inhibition results 
are shown in Table 3.  
Ulcerogenicity 
Ulceration in rats was induced as reported method [20]. Albino rats 
of Wistar strain weighing 150–200 g of either sex were divided into 
various groups each of six animals. Control group of animals were 
administered only with 10% v/v Tween-80 suspension 
intraperitoneally. One group was administered with aspirin 
intraperitoneally in a dose of 200 mg/kg once daily for 3 days. 
Diclofenac was also administered as standard drug at 20 mg/kg once 
daily for 3 days to another group of animals in the same route.  
The remaining group of animals was administered with test 
compounds intraperitoneally in a dose of 20 mg/kg. On fourth day, 
pylorus was ligated as per previous reported method [21]. Animals 
were fasted for 36 h before the pylorus ligation procedure. Four 
hours after the ligation, animals were sacrificed. The stomach was 
removed and opened along with the greater curvature. Ulcer index 
was determined by earlier reported method [22]. 
Anti microbial activity 
In this study, all the synthesized compounds were screened for 
antimicrobial activity by agar streak dilution method. The 
antibacterial activity of the compounds were evaluated against four 
Gram-positive bacteria Staphylococcus aureus ATCC 9144, 
Staphylococcus epidermidis ATCC 155, Micrococcus luteus ATCC 4698 
and Bacillus cereus ATCC 11778 and three Gram-negative bacteria 
Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 2853, 
and Klebsiella pneumoniae ATCC 11298. The antifungal activities of 
the synthesized compounds were evaluated against two fungi 
Aspergillus niger ATCC 9029 and Aspergillus fumigatus ATCC 46645. 
Bacterial strains were cultured over night at 37°C in Mueller–Hinton 
broth and the yeast was cultured overnight at 30°C in YEPDE agar 
for antibacterial and antifungal activity tests. Test strains were 
suspended in nutrient agar to give a final density of 5 x 10-5
Minimum inhibitory concentration (MIC) 
 cfu/ml. 
MIC of the compound was determined by agar streak dilution 
method [23]. A stock solution of the synthesized compound (100 
µg/ml) in dimethyl formamide was prepared and graded quantities 
of the test compounds were incorporated in a specified quantity of 
molten sterile agar (nutrient agar for anti-bacterial activity and 
Sabouraud’s dextrose agar medium for anti-fungal activity). A 
specified quantity of the medium (40-50°C) containing the 
compound was poured into a petridish to give a depth of 3-4 mm 
and allowed to solidify. Suspension of the micro-organism were 
prepared to contain approximately 5 x 10-5 cfu/ml and applied to 
plates with serially diluted compounds in dimethyl formamide to be 
tested and incubated at 37°
RESULTS AND DISCUSSION 
C for 24 h and 48 h for bacteria and fungi, 
respectively. The MIC was considered to be the lowest concentration 
of the test substance exhibiting no visible growth of bacteria or fungi 
on the plate. 
Chemistry 
In this study, we synthesized a series of novel Schiff and mannich 
bases of isatin derivative by substituting different aromatic 
aldehydes at the 3rd position through thiazole ring. And 
dimethylamino group at the N-1 position with formalin. Initially, 5-
fluoro isatin and p-amino acetophenone were used as starting 
materials to produce 3-(4-acetylphenylimino)-5-fluoroindolin-2-one 
by a condensation reaction, which proceeds selectively on the 
carbonyl group in position 3 of the isatin ring. Furthermore, this 
compound was treated with dimethylamine and formalin gave 3-(4-
acetylphenylimino)-1-((dimethylamino)methyl)-5-fluoroindolin-2-
one. In this way the formed mannich base is reacted with thiourea in 
presence of bromine to offered a cyclic thiazole compound namely 
3-(4-(2-aminothiazol-4-yl) phenylimino)-1- ((dimethyl amino) 
methyl)-5-fluoroindolin-2-one. Finally this compound was treated 
with different aromatic aldehydes in the presence of glacial acetic 
acid, and a variety of Schiff base derivatives have been isolated 
according to the synthetic Scheme 1. IR, 1H-NMR, mass spectra, and 
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elemental analyses of the synthesized compounds are in accordance 
with the assigned structures. The IR spectra of all synthesized 
compounds showed some characteristic peaks indicating the 
presence of particular groups. The absorption bands at, around 1725 
cm-1, and weak band around 1650 cm-1, which can be assignable to 
C=O, and C=N (azomethine linkage) vibrations respectively.  
IR spectrum of 3-(4-(2-(4-hydroxybenzylideneamino)thiazol-4-
yl)phenylimino)-1-((dimethylamino)methyl)-5-fluoroindolin-2-one 
(5k) was shown in the absorption band in the region of 3415 cm-
1 
• A intense singlet around 2.5 ppm for N, N-dimethyl group,  
which may be assigned to O–H stretching. The proton magnetic 
resonance spectrums of synthesized compounds were recorded in 
DMSO-d6. The following conclusions can be derived by comparing 
the spectra of synthesized compounds:  
• A singlet about 8.2 for N=CH group,  
• A singlet about 4.3 ppm corresponding to -CH2
Biological activity 
- group for 
methylene derivatives  
Analgesic activity 
All the test compounds 5a-5l was evaluated for their analgesic 
activity by tail-flick technique using Wistar albino mice. The results 
of analgesic study are summarized in Table 1. The reports indicate 
that all the test compounds exhibited significant activity and graded 
dose response. Moreover, this study revealed that test compounds 
showed moderate analgesic activity at 30 min of reaction time; the 
activity increased at 1 h, further it reached to peak level at 2 h and 
past its best in activity was observed at 3 h. Compound 5a with 
unsubstituted phenyl derivative showed moderate analgesic activity 
compared to standard drug Diclofenac sodium. With the increased 
lipophilicity dimethyl amino and o-chloro substituted derivatives 
(5d and 5h) showed an increase in activity. When methyl (5b) and 
chlorine (5g) group substituted at para position further increases 
the lipophilicity results in enhanced activity which was found to be 
more potent than standard drug tested. Insertion of nitro and/or 
hydroxyl group (5i-5l) leads to decreases in activity which may be 



































5c = 4-OH, 3-OCH3
5d = 4-N(CH3)2
5e = 4-OCH3
5f  = 3,4,5-(OCH3)3
5g = 4-Cl
5h = 2-Cl
5i  = 4-NO2
5j  = 3-NO2
5k  = 4-OH
5l  = 2-OH
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 Anti-inflammatory activity 
Carrageenan-induced paw edema test was performed to assess the 
anti-inflammatory activity of test compounds using Wistar rats. The 
anti-inflammatory activity results (Table 2) showed that all the test 
compounds protected rats from carrageenan-induced inflammation 
reasonably at 30 min of reaction time; the activity increased at 1 h 
and it reached to maximum level at 2 h. Declining in activity was 
observed at 3 h. The compounds possessing unsubstituted phenyl 
ring 5a exhibited moderate anti-inflammatory activity when 
compared to the reference standard Diclofenac sodium. With 
increased lipophilicity the compound 5d and 5h showed equipotent 
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activity with reference standard Diclofenac sodium. Among all tested 
compounds methyl (5b) and chlorine (5g) placed at para position 
analogues exhibited better activity which is more potent than 
diclofenac. A deep fall in activity was observed when insertion of 
methoxy or nitro or hydroxyl group. 
Ulcerogenicity: Further all the test compounds were examined for 
its ulcerogenicity and the results are summarized in Table 3. Entire 
test compounds exhibited less ulcer index compared to standard 
Diclofenac and Aspirin. The test compounds exhibited ulcer index 
ranging from 0.53±0.12 to 0.96±0.18 compared to the reference 
drug Diclofenac (1.60±0.52) and Aspirin (1.72±0.33).  
The most potent compound of these series 5d and 5g found to 
possess only one third of the ulcer index of reference standards 
(Diclofenac and Aspirin). 
 
Table 1: Analgesic activity of the test compounds (5a-5l) by Tail flick method 
Compound Dose (mg/kg) Percent analgesic activity 
30 min 1 h 2 h 3 h 
5a 10 25±1.81* 41±0.58** 45±0.26* 24±1.62** 
20 37±1.28* 42±0.03* 49±1.13** 30±0.84* 
5b 10 36±0.52** 45±0.56* 50±1.21* 32±1.56* 
20 53±0.54* 58±1.65* 68±1.96* 47±0.52* 
5c 10 27±1.31* 39±0.08* 42±0.95** 25±1.35** 
20 43±1.06* 47±0.61** 56±1.03* 36±0.77* 
5d 10 33±1.36* 42±0.87* 47±0.87** 29±1.64** 
20 49±1.75** 52±0.67* 64±0.41* 44±1.32* 
5e 10 29±1.51* 41±0.38* 44±0.16* 27±1.45** 
20 46±1.18* 50±0.95* 60±1.54* 39±0.79* 
5f 10 22±0.81** 34±1.43* 39±0.38* 24±1.14* 
20 36±0.89* 41±2.53* 47±0.64** 30±1.14* 
5g 10 38±0.66** 47±0.42* 53±1.52* 34±1.84* 
20 55±0.54* 61±1.22** 72±1.89* 49±0.85** 
5h 10 31±0.47* 42±0.35* 46±1.30* 27±1.66* 
20 47±0.48* 52±1.43* 64±1.06* 44±0.69* 
5i 10 18±2.01*** 24±1.45* 28±0.35* 16±1.47** 
20 29±2.70** 33±1.36** 38±0.77** 22±1.84* 
5j 10 17±0.79* 23±1.80* 26±1.35* 14±0.55* 
20 24±0.66* 31±1.87** 35±0.40* 18±1.54* 
5k 10 23±1.99** 33±0.77* 38±1.34* 25±0.35*** 
20 35±1.78* 42±0.52* 46±1.64** 29±2.01* 
5l 10 21±1.57* 31±0.22* 35±1.29* 20±0.45* 
20 32±1.12* 39±0.44* 42±1.18** 27±1.03* 
Control - 03±0.35 05±0.56 06±0.72 04±0.55 
Diclofenac 10 32±1.16* 43±1.54** 47±0.44** 28±1.36* 
20 48±1.43** 53±0.68*** 64±0.38* 45±1.56** 
Each value represents mean + SEM (n = 6); Significance levels *P < 0.05, **P < 0.01, ***P < 0.001 
 
Table 2: Anti-inflammatory activity of the test compounds (5a-5l) by Carrageenan induced rat paw oedema test 
Compound Dose (mg/kg) Percent protection 
30 min 1 h 2 h 3 h 
5a 10 25±0.55* 33±1.03* 39±0.54* 26±0.45** 
20 38±0.56** 46±0.47** 55±1.14* 35±2.01* 
5b 10 34±0.65* 39±1.24* 44±1.11* 31±0.24* 
20 44±0.27* 54±0.23* 63±0.45** 47±0.64* 
5c 10 23±0.41* 31±0.63* 33±1.52* 21±0.63** 
20 32±2.01* 40±0.43** 47±1.12* 28±1.34* 
5d 10 30±1.01* 37±0.44* 42±0.09* 29±1.47* 
20 42±0.42* 51±0.15** 61±0.47* 42±0.64* 
5e 10 23±1.41** 31±1.32* 36±0.47** 24±1.02* 
20 36±1.10* 44±1.36* 52±0.36* 32±2.00*** 
5f 10 22±0.52* 30±1.04* 34±0.22* 22±0.55* 
20 34±0.77* 42±1.63** 50±1.21* 30±0.64* 
5g 10 36±1.41* 41±0.54* 46±0.66** 33±2.02* 
20 46±0.21** 56±1.06* 68±0.15* 50±1.02* 
5h 10 30±1.45* 36±1.10** 42±1.32* 29±0.42* 
20 40±0.96* 51±1.24* 61±0.16* 42±0.63*** 
5i 10 19±0.54** 28±1.14* 29±1.47** 18±0.45* 
20  26±0.41* 34±1.14*** 40±1.41* 24±1.21*** 
5j 10 18±1.51* 26±2.02** 26±0.48* 17±1.19* 
20 24±1.04* 32±0.14* 38±1.26* 22±0.24* 
5k 10 22±1.32* 31±0.33** 32±0.64** 20±1.03* 
20 31±1.41*** 39±0.61* 45±0.11* 27±1.34*** 
5l 10 21±0.45* 30±1.34* 31±1.01** 20±0.42* 
20 29±1.26* 37±0.46* 43±1.31* 26±1.18* 
Control - 4.1±0.94 6.7±0.56 4.9±0.23 3.1±0.51 
Diclofenac 10 31±0.41** 37±0.41* 42±1.74* 30±1.01** 
 20 42±0.64* 52±1.45*** 61±0.44** 43±1.11* 
Aspirin 200 - - - - 
Each value represents mean + SEM (n = 6); Significance levels *P < 0.05, **P < 0.01, ***P < 0.001 
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Table 3: Ulcer index of the test compounds (5a-5l) by pylorus ligation method. 
Compound Dose (mg/kg) Ulcer index 
5a 20 0.71±0.62 
5b 20 0.60±0.34 
5c 20 0.74±0.28 
5d 20 0.55±0.12 
5e 20 0.66±0.18 
5f 20 0.82±0.50 
5g 20 0.54±0.32 
5h 20 0.68±0.42 
5i 20 0.90±0.44 
5j 20 0.96±0.18 
5k 20 0.62±0.46 
5l 20 0.74±0.16 
Control - 0.14±0.24 
Diclofenac 20 1.60±0.52 
Aspirin 200 1.72±0.33 
 
Table 4: MIC (Minimum inhibitory concentration in µg/ml) of synthesized compounds (5a-5l) 
Compounds K. pneumoniae E. coli P. aeruginosa M. luteus B. cereus S. epidermidis S. aureus A. fumigatus A. niger 
5a 15.62 31.25 15.62 31.25 31.25 15.62 31.25 15.62 31.25 
5b 7.81 31.25 7.81 15.62 15.62 7.81 31.25 7.81 31.25 
5c 15.62 31.25 31.25 15.62 31.25 15.62 31.25 7.81 31.25 
5d 3.9 7.81 15.62 7.81 15.62 15.62 15.62 15.62 15.62 
5e 7.81 31.25 7.81 31.25 31.25 15.62 31.25 31.25 15.62 
5f 15.62 31.25 31.25 31.25 62.5 31.25 31.25 15.62 31.25 
5g 3.9 31.25 7.81 31.25 31.25 7.81 15.62 7.81 31.25 
5h 31.25 15.62 31.25 31.25 15.62 31.25 31.25 15.62 31.25 
5i 15.62 62.5 15.62 31.25 31.25 31.25 62.5 62.5 62.5 
5j 31.25 31.25 15.62 62.5 62.5 62.5 31.25 15.62 62.5 
5k 7.81 15.62 15.62 7.81 31.25 15.62 15.62 15.62 15.62 
5l 15.62 31.25 15.62 7.81 31.25 31.25 31.25 15.62 31.25 
Ciprofloxacin 3.9 15.62 7.81 7.81 15.62 7.81 15.62 - - 
Ketoconazole - - - - - - - 7.81 15.62 
 
Antimicrobial activity 
All the synthesized compounds were subjected to MIC (minimum 
inhibitory concentration) studies against all the microorganisms. 
The MICs of Ciprofloxacin and Ketoconazole were determined in 
parallel experiments in order to control the sensitivity of the test 
organisms. MIC values of the compounds and the standards are 
presented in Table 4. As seen in table 4 all compounds showed lower 
activities (MIC: 7.81-31.25 µg/ml) than standard against K. 
pneumoniae except 5d and 5g which showed equal activity. When it 
comes to E. coli compound 5d demonstrated exceptionally  
outstanding activity (MIC: 7.81 µg/ml) than Ciprofloxacin (MIC: 
15.62 µg/ml), while compounds 5h and 5k showed equipotent 
activity against. Compounds 5c, 5f and 5h showed least activity 
(MIC: 31.25 µg/ml) against P. aeruginosa. Compounds 5d, 5k and 5l 
showed at par activity with standard against M. luteus (MIC: 7.81 
µg/ml). Two compounds 5f and 5j showed least activity (MIC: 62.5 
µg/ml) against B. cereus. Except compound 5b and 5g remaining 
compounds offered less activity than standard against S. epidermidis. 
Compounds 5d, 5g and 5k exhibited same activity (MIC: 15.62 
µg/ml) as ciprofloxacin against S. aureus. While remaining 
compounds exhibited lesser activity (MIC: 31.25-62.5 µg/ml). Equal 
activity was produced by compounds 5b, 5c and 5g against A. 
fumigatus as standard, while remaining compounds showed lower 
activity (MIC: 15.62-62.5 µg/ml). Compounds 5d, 5e and 5k showed 
equal activity (MIC: 15.62 µg/ml) against A. niger when compared 
with standard drug ciprofloxacin (MIC: 15.62 µg/ml). Remaining 
other compounds has lower activity (MIC: 31.25-62.5 µg/ml). 
CONCLUSIONS 
In conclusion, we report the synthesis of novel isatin Schiff and 
mannich bases by incorporating thiazole moiety using inexpensive 
and commercially available materials with potential medicinal 
properties. This synthesis benefits from a simple method of 
purification. This ease of purification compliments this synthetic 
technology practical, easy to perform and facile. The synthesized 
compounds are characterized by FT-IR, 1
 Compounds 5b and 5k showed moderated activity in the 
antimicrobial studies. While compounds 5d and 5g showed 
outstanding activity compared to standard drugs in the 
antimicrobial studies. Among all the test compounds, it is interesting 
to note that compounds 5d and 5g showed best antimicrobial, anti-
inflammatory and analgesic activity with less ulcer index. 
H-NMR, mass spectroscopy 
and elemental analysis. These derivatives were evaluated for their in 
vitro antimicrobial, analgesic and anti-inflammatory activity. It has 
been found that the derivatives 5a, 5c, 5d, 5e and 5h showed 
comparable analgesic and anti-inflammatory activity equal to 
standard. While compound 5b and 5g exhibited more analgesic and 
anti-inflammatory activity compared to the reference drugs. 
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